CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
2.000
+0.080 (4.17%)
Nov 14, 2025, 4:00 PM EST - Market closed
CytoMed Therapeutics Income Statement
Financials in millions SGD. Fiscal year is January - December.
Millions SGD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
Operating Revenue | 0.23 | 0.07 | - | - | - | - | Upgrade |
Other Revenue | 0.5 | 0.43 | 0.51 | 0.36 | 0.11 | 0.06 | Upgrade |
| 0.73 | 0.5 | 0.51 | 0.36 | 0.11 | 0.06 | Upgrade | |
Revenue Growth (YoY) | 63.03% | -0.86% | 39.52% | 219.67% | 91.43% | - | Upgrade |
Cost of Revenue | 0.05 | 0.03 | 0 | 0.01 | 0 | 0 | Upgrade |
Gross Profit | 0.68 | 0.47 | 0.5 | 0.36 | 0.11 | 0.05 | Upgrade |
Selling, General & Admin | 0.74 | 0.65 | 0.49 | 0.21 | 0.17 | 0.14 | Upgrade |
Research & Development | 2.1 | 1.91 | 1.59 | 1.52 | 1.09 | 1.04 | Upgrade |
Amortization of Goodwill & Intangibles | 0.03 | 0.01 | 0 | 0 | 0 | 0 | Upgrade |
Other Operating Expenses | 0.83 | 0.92 | 2.16 | 0.37 | 0.49 | 0.11 | Upgrade |
Operating Expenses | 4.2 | 3.6 | 4.35 | 2.21 | 1.85 | 1.37 | Upgrade |
Operating Income | -3.52 | -3.13 | -3.84 | -1.86 | -1.74 | -1.32 | Upgrade |
Interest Expense | -0.02 | -0.02 | -0.05 | -0.13 | -0.12 | -0.11 | Upgrade |
Interest & Investment Income | 0.21 | 0.32 | 0.29 | 0 | 0 | - | Upgrade |
Earnings From Equity Investments | -0.01 | 0.01 | -0.03 | -0.03 | -0.21 | - | Upgrade |
Currency Exchange Gain (Loss) | -0.24 | 0.16 | -0.17 | -0.03 | -0.01 | -0 | Upgrade |
Other Non Operating Income (Expenses) | -0.09 | 0.14 | -0.22 | - | - | - | Upgrade |
EBT Excluding Unusual Items | -3.67 | -2.52 | -4.03 | -2.04 | -2.08 | -1.42 | Upgrade |
Gain (Loss) on Sale of Assets | -0 | - | - | 0 | - | - | Upgrade |
Other Unusual Items | - | - | -0.1 | -1.09 | 0.02 | -0.51 | Upgrade |
Pretax Income | -3.68 | -2.52 | -4.13 | -3.13 | -2.05 | -1.94 | Upgrade |
Income Tax Expense | - | - | 0 | 0 | - | - | Upgrade |
Earnings From Continuing Operations | -3.68 | -2.52 | -4.13 | -3.13 | -2.05 | -1.94 | Upgrade |
Minority Interest in Earnings | 0.01 | 0.01 | 0 | 0 | 0 | 0 | Upgrade |
Net Income | -3.67 | -2.52 | -4.13 | -3.13 | -2.05 | -1.94 | Upgrade |
Net Income to Common | -3.67 | -2.52 | -4.13 | -3.13 | -2.05 | -1.94 | Upgrade |
Shares Outstanding (Basic) | 12 | 12 | 11 | 8 | 7 | 6 | Upgrade |
Shares Outstanding (Diluted) | 12 | 12 | 11 | 8 | 7 | 6 | Upgrade |
Shares Change (YoY) | - | 8.56% | 34.30% | 14.14% | 17.59% | 6.22% | Upgrade |
EPS (Basic) | -0.32 | -0.22 | -0.39 | -0.40 | -0.30 | -0.33 | Upgrade |
EPS (Diluted) | -0.32 | -0.22 | -0.39 | -0.40 | -0.30 | -0.33 | Upgrade |
Free Cash Flow | -3.99 | -4.11 | -3.59 | -1.87 | -2.3 | -1.09 | Upgrade |
Free Cash Flow Per Share | -0.35 | -0.36 | -0.34 | -0.24 | -0.33 | -0.19 | Upgrade |
Gross Margin | 92.52% | 93.83% | 99.27% | 97.60% | 96.92% | 92.22% | Upgrade |
Operating Margin | -482.59% | -621.91% | -756.86% | -511.02% | -1528.84% | -2215.85% | Upgrade |
Profit Margin | -503.11% | -499.97% | -813.98% | -860.43% | -1802.21% | -3254.59% | Upgrade |
Free Cash Flow Margin | -546.82% | -816.52% | -706.96% | -514.47% | -2016.27% | -1839.93% | Upgrade |
EBITDA | -3.18 | -2.8 | -3.46 | -1.47 | -1.41 | -1.03 | Upgrade |
D&A For EBITDA | 0.34 | 0.33 | 0.38 | 0.39 | 0.33 | 0.29 | Upgrade |
EBIT | -3.52 | -3.13 | -3.84 | -1.86 | -1.74 | -1.32 | Upgrade |
Advertising Expenses | - | 0.02 | 0.03 | - | 0 | 0.01 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.